Juan Carlos Juárez Cruz, Adriana Soto Guzmán, Angélica Martínez López, Napoleón Navarro Tito


Actualmente la obesidad y el cáncer mamario representan un importante problema de salud pública dada la elevada frecuencia de ambas condiciones en la población a nivel mundial. Esta revisión tiene como objetivo el presentar información actual sobre la obesidad como factor de riesgo contribuyente con el inicio y progresión del cáncer de mama a través de la recopilación y presentación de evidencia científica actualizada. Múltiples estudios realizados en humanos, in vitro y en modelos animales evidencian una relación entre la obesidad como un factor de riesgo importante en el desarrollo y progresión del cáncer de mama. Sin embargo, esta relación es más profunda ya que involucra como participante activo al tejido adiposo.

Palabras clave

obesidad; cáncer de mama; factor de riesgo

Texto completo:



Aguilar Cordero, M. J., González Jiménez, E., García López, A. P., Álvarez Ferré, J., Padilla López, C. A., Guisado Barrilao, y Rizo Baeza, M, 2011. Obesidad y su implicación en el cáncer de mama. Nutrición Hospitalaria. 26: 899-903.

Alokail, M. S., Al-Daghri, N. M., Al-Attas, O. S. y Hussain, T. 2009. Combined effects of obesity and type 2 diabetes contribute to increased breast cancer risk in premenopausal women. Cardiovascular Diabetology. 8: 33.

Anaya-Ruiz, M., Vallejo-Ruiz, V., Flores-Mendoza, L. y Perez- Santos, M. 2014. Female breast cancer incidence and mortality in Mexico, 2000-2010. Asian Pacific Journal of Cancer Prevention. 15(3):1477-9.

Argolo D.F., Hudis C.A. y Iyengar N.M. 2018. The Impact of Obesity on Breast Cancer. Current Oncology Reports. 20:47.

Assiri, A. M., Kamel, H. F. y Hassanien, M. F. 2015. Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers. Disease Markers, 253519.

Atoum, M., Al-Hourani, H., Nimer, N., Almuhrib, T. y Raheem, S. 2012. Endogenous estradiol, estrogen and progesterone receptors increase benign and breast cancer risk among non-familial postmenopausal females. Health Science Journal. 6: 693-702.

Azrad, M. y Demark-Wahnefried, W. 2014. The association between adiposity and breast cancer recurrence and survival: A review of the recent literature. Current Nutrition Reports. 3: 9-15.

Babaei, Z., Moslemi, D., Parsian, H., Khafri, S., Pouramir, M. y Mosapour, A. 2015. Relationship of obesity with serum concentrations of leptin, CRP and IL-6 in breast cancer survivors. Journal of the Egyptian National Cancer Institute. 27: 223-9.

Barakat, R., Oakley, O., Kim, H., Jin, J. y Ko, C. J. 2016. Extragonadal sites of estrogen biosynthesis and function. BMB Reports. 49: 488-496.

Benjamin, M. A. y Riker, A. I. 2015. A Case of Male Breast Cancer with a BRCA Gene Mutation. Ochsner J, 15: 448-51.

Bolton, J. L. y Thatcher, G. R. 2008. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol, 21: 93-101.

Brinton, L. A. 2011. Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatrica. 100: 814-8.

Brinton, L. A., Cook, M. B., Mccormack, V., Johnson, K. C., Olsson, H., Casagrande, J. T., Cooke R., Falk R.T., Gapstur S.M., Gaudet M.M., Gaziano J.M., Gkiokas G,. Guénel P., Henderson B.E., Hollenbeck A., Hsing A.W., Kolonel L.N., Isaacs C., Lubin J.H., Michels K.B., Negri E., Parisi D., Petridou E.T., Pike M.C., Riboli E., Sesso H.D., Snyder K., Swerdlow A.J.; European Rare Cancer Study Group, Trichopoulos D., Ursin G., van den Brandt P.A., Van Den Eeden S.K., Weiderpass E., Willett W.C., Ewertz M. y Thomas D.B. 2014. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. Journal of the National Cancer Institute. 106(3):djt465.

Buicko, J. L., Lopez, M. A. y Lesnikoski, B. A. 2017. Breast Cancer in a Male with BRCA2 Mutation: Is Screening Mammography Necessary in Men? Clinics in Surgery. 2: 1-3.

Bulun, S. E., Chen, D., Moy, I., Brooks, D. C. y Zhao, H. 2012. Aromatase, breast cancer and obesity: a complex interaction. Trends in Endocrinology & Metabolism. 23: 83-9.

Caldon, C. E. 2014. Estrogen signaling and the DNA damage response in hormone dependent breast cancers. Frontiers in Oncology. 4: 106.

Carmichael, A. R. y Bates, T. 2004. Obesity and breast cancer: a review of the literature. Breast. 13: 85-92.

Carroll, J. P., Protani, M. M., Nguyen, L., Cheng, M. E., Fay, M., Saleem, M., Pillay P.S., Walpole E y Martin J.H. 2014. Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. Medical Oncology. 31: 881.

Catalano, S., Marsico, S., Giordano, C., Mauro, L., Rizza, P., Panno, M. L. y Andò S. 2003. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. The Journal of Biological Chemistry. 278: 28668-76.

Colleoni, M., Li, S., Gelber, R. D., Price, K. N., Coates, A. S., Castiglione-Gertsch, M., y Goldhirsch A. 2005. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 366: 1108-10.

Dalamaga M., Sotiropoulos G., Karmaniolas K., Pelekanos N., Papadavid E. y Lekka A. 2013. Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clinical Biochemistry. 46:584-90.

Dawood, S., Broglio, K., Gonzalez-Angulo, A. M., Kau, S. W., Islam, R., Hortobagyi, G. N. y Cristofanilli M. 2008. Prognostic value of body mass index in locally advanced breast cancer. Clinical Cancer Research. 14: 1718-25.

Dodge, D. J. y Kejel, J. L. 2006. Advances in Breast Cancer Screening and Diagnosis. The Journal of Lancaster General Hospital. 1: 47-51.

El-Tamer, M. B., Ward, B. M., Schifftner, T., Neumayer, L., Khuri, S. y Henderson, W. 2007. Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Annals of Surgery. 245: 665-71.

Esquivel-Velazquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I. y Morales-Montor, J. 2015. The role of cytokines in breast cancer development and progression. Journal of Interferon & Cytokine Research. 35: 1-16.

Field, K. M., Kosmider, S., Jefford, M., Michael, M., Jennens, R., Green, M., y Gibbs P. 2008. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. Journal of Oncology Practice. 4: 108-13.

Fischer, J. P., Nelson, J. A., Kovach, S. J., Serletti, J. M., Wu, L. C. y Kanchwala, S. 2013. Impact of obesity on outcomes in breast reconstruction: analysis of 15,937 patients from the ACS-NSQIP datasets. Journal of the American College of Surgeons. 217: 656-64.

Garofalo, C., Koda, M., Cascio, S., Sulkowska, M., Kanczuga-Koda, L., Golaszewska, J., Russo, A., Sulkowski, S. y Surmacz, E. 2006. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clinical Cancer Research. 12: 1447-53.

Gerard, C. y Brown, K. A. 2017. Obesity and breast cancer - Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue. Molecular and Cellular Endocrinology. (article in press). Ghoncheh, M., Pournamdar, Z., y Salehiniya, H. 2016. Incidence

and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific Journal of Cancer Prevention. 17: 43-6.

Gnerlich, J. L., Deshpande, A. D., Jeffe, D. B., Seelam, S., Kimbuende, E. y Margenthaler, J. A. 2011. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Annals of Surgical Oncology. 18: 1837-44.

González-Robledo, M.C., Wong R., Ornelas, H.A. y Knaul, F.M. 2015. Costs of breast cancer care in Mexico: analysis of two insurance coverage scenarios. Ecancermedicalscience. 28: 587.

Grajales-Pérez, E. G., Cazares-Flores, C., Díaz-Amezquita, L. y De Alba-Ramírez, V. 2014. Factores de riesgo para el cáncer de mama en México: revisión de estudios en poblaciones mexicanas y México-americanas. CES Salud Pública. 5: 50-58.

Greenman, C. G., Jagielski, C. H. y Griggs, J. J. 2008. Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice. Cancer. 112: 2159-65.

Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., Morrison, V. A., Pini, T.M., Runowicz, C.D., Rosner, G.L., Shayne, M., Sparreboom, A., Sucheston, L.E. y Lyman, G.H. 2012. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. Journal of

Clinical Oncology. 30: 1553-61.

Gui, Y., Pan, Q., Chen, X., Xu, S., Luo, X., y Chen, L. 2017. The association between obesity related adipokines and risk of breast cancer: a meta-analysis. Oncotarget. 8:75389–75399.

Haakinson, D. J., Leeds, S. G., Dueck, A. C., Gray, R. J., Wasif, N., Stucky, C. C., Northfelt, D. W., Apsey, H.A. y Pockaj, B. 2012. The impact of obesity on breast cancer: a retrospective review. Annals of Surgical Oncology. 19: 3012-8.

Hao S., Liu Y., Yu K-D., Chen S., Yang W-T., y Shao Z-M. 2015. Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women. PLoS ONE. 10: e0129741.

Hauck, K. y Hollingsworth, B. 2010. The impact of severe obesity on hospital length of stay. Medical Care. 48: 335-40.

Hourdequin, K. C., Schpero, W. L., Mckenna, D. R., Piazik, B. L. y Larson, R. J. 2013. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Annals of Oncology. 24: 2952-62.

Hosney, M., Sabet, S., El-Shinawi, M., Gaafar, K. M., y Mohamed, M. M. 2017. Leptin is overexpressed in the tumor microenvironment of obese patients with estrogen receptor positive breast cancer. Experimental and Therapeutic Medicine, 13: 2235–2246.

Hovey, R. C. y Aimo, L. 2010. Diverse and active roles for adipocytes during mammary gland growth and function. Journal of Mammary Gland Biology and Neoplasia. 15: 279-90.

Humphries, M. P., Jordan, V. C. y Speirs, V. 2015. Obesity and male breast cancer: provocative parallels? BMC Medicine. 13: 134.

Hung A.C., Lo S., Hou M.F., Lee Y.C., Tsai C.H., Chen Y.Y., Liu W., Su Y.H., Lo Y.H., Wang C.H., Wu S.C., Hsieh Y.C., Hu S.C., Tai M.H., Wang Y.M. y Yuan S.S. 2016. Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation. Clinical Cancer Research. 22:4478-90.

IMCO 2015. Kilos De Más, Pesos De Menos - Los Costos De La Obesidad En México. Instituto Mexicano para la Competitividad. 1-47.

INEGI 2015. Estadísticas A Propósito Del Día Mundial De La Lucha Contra El Cáncer De Mama (19 De Octubre). Instituto Nacional de Estadística y Geografía (INEGI). 1-14.

INSP 2016. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016 (ENSANUT 2016) Informe final de resultados. Secretaria de Salud - Instituto Nacional de Salud Pública. 1-149.

Ishikawa, M., Kitayama, J. y Nagawa, H. 2004. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clinical Cancer Research. 10: 4325-31.

Kaviani, A., Neishaboury, M., Mohammadzadeh, N., Ansari- Damavandi, M. y Jamei, K. 2013. Effects of Obesity on Presentation of Breast Cancer, Lymph Node Metastasis and Patient Survival: A Retrospective Review. Asian Pacific Journal of Cancer Prevention. 14: 2225-2229.

Kerlikowske, K., Walker, R., Miglioretti, D. L., Desai, A., Ballard- Barbash, R. y Buist, D. S. 2008. Obesity, mammography use and accuracy, and advanced breast cancer risk. Journal of the National Cancer Institute. 100: 1724-33.

Kimbung, S., Loman, N. y Hedenfalk, I. 2015. Clinical and molecular complexity of breast cancer metastases. Seminars in Cancer Biology. 35, 85-95.

Knaul, F. M., Nigenda, G., Lozano, R., Arreola-Ornelas, H., Langer, A. y Frenk, J. 2009. Cáncer de mama en México: una prioridad apremiante. Salud Pública de México. 51: s335-s344.

Koksal H., Ugras N. S., Kurban S., Harmankaya I., Atay A., Eren Karanis M. I. y Dogru O. 2017. Serum Visfatin Levels and Tissue Visfatin Expression in Patients with Breast Diseases. Clinics in Surgery. 2:1-4.

Korkaya, H., Liu, S. y Wicha, M. S. 2011. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. The Journal of Clinical Investigation. 121: 3804-9.

Kotsopoulos, J., Olopado, O. I., Ghadirian, P., Lubinski, J., Lynch, H. T., Isaacs, C., Weber B., Kim-Sing C., Ainsworth P., Foulkes WD., Eisen A., Sun P. y Narod SA. 2005. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research. 7: R833-43.

Lazzeroni M., Dunn B.K., Pruneri G., Jereczek-Fossa B.A., Orecchia R., Bonanni B., y DeCensi A. 2017. Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora’s box. Cancer Treatment Reviews. 55:1-9.

Lyon, D. E., Mccain, N. L., Walter, J. y Schubert, C. 2008. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nursing Research. 57: 51-8.

McPherson, K., Steel, C. M. y Dixon, J. M. 2000. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 321: 624-8.

McTiernan, A. 2003. Behavioral risk factors in breast cancer: can risk be modified? Oncologist. 8: 326-34.

Navarro, W. H. 2003. Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplantation. 31: 961-6.

Neuhouser, M. L., Aragaki, A. K., Prentice, R. L., Manson, J. E., Chlebowski, R., Carty, C. L., Ochs-Balcom, H.M., Thomson, C.A., Caan, B.J., Tinker, L.F., Urrutia, R.P., Knudtson, J. y Anderson, G.L. 2015. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials. JAMA Oncology. 1: 611-21.

Niewoehner, C. B. y Schorer, A. E. 2008. Gynaecomastia and breast cancer in men. BMJ. 336: 709-13.

OECD 2017. Obesity Update 2017. Organisation for Economic Co-operation and Development. 1-13.

Osman, M. A. y Hennessy, B. T. 2015. Obesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast Cancer. Clinical Medicine Insights: Oncology. 9: 105-12.

Pi-Sunyer, X. 2009. The medical risks of obesity. Postgraduate Medical Journal. 121: 21-33.

Pollock, N. J. 1995. Cultural elaborations of obesity - fattening practices in Pacific societies. Asia Pacific Journal of Clinical Nutrition. 4: 357-60.

Porter, G. A., Inglis, K. M., Wood, L. A. y Veugelers, P. J. 2006. Effect of obesity on presentation of breast cancer. Annals of Surgical Oncology. 13: 327-32.

Renehan, A. G., Harvie, M., Cutress, R. I., Leitzmann, M., Pischon, T., Howell, S. y Howell, A. 2016. How to Manage the Obese Patient With Cancer. Journal of Clinical Oncology. 34: 4284-4294.

Reynoso-Noveron, N., Villarreal-Garza, C., Soto-Perez-de Celis, E., Arce-Salinas, C., Matus-Santos, J., Ramírez-Ugalde, M.T., Alvarado-Miranda, A., Cabrera-Galeana, P., Meneses-García, A., Lara-Medina, F., Bargalló-Rocha, E. y Mohar, A. 2017. Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular. American Society of Clinical Oncology. 3 (6):757-764.

Segula, D. 2014. Complications of obesity in adults: a short review of the literature. Malawi Medical Journal. 26: 20-4.

Shouman, S., Wagih, M. y Kamel, M. 2016. Leptin influences estrogen metabolism and increases DNA adduct formation in breast cancer cells. Cancer Biology & Medicine. 13: 505-513.

Sobal, J. 2001. Social and Cultural Influences on Obesity, in International Textbook of Obesity (ed P. Björntorp). International Textbook of Obesity, John Wiley & Sons, Ltd, Chichester, UK. 305-322.

Soto-Molina, H., Ascencio-Pérez, I., Azamar-Alonso, A., Díaz- Martínez, J., Pizarro-Castellanos, M., Fernández-Del Valle Laisequilla, C., Reyes-García, J.G., Botello-Estrada, B., y, A. 2015. Carga económica de la obesidad y sus comorbilidades en pacientes adultos en México. PharmacoEconomics

Spanish Research Articles. 12: 115–122.

Tallón-Aguilar, L., Serrano-Borrero, I., López-Porras, M., Sousa- Vaquero, J. y De León-Carrillo, J. 2011. Cáncer de mama en el varón. Cirugía y Cirujanos 79: 320-323.

Telli, M. L. y Carlson, R. W. 2009. First-line chemotherapy for metastatic breast cancer. Clinical Breast Cancer. 9: S66-72.

Truswell, A. S. 2013. Medical History Of Obesity. Nutrition and Medicine. 1: 1-25.

Turkoz, F. P., Solak, M., Petekkaya, I., Keskin, O., Kertmen, N., Sarici, F., Arik Z., Babacan, T., Ozisik, Y. y Altundag, K. 2013. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. Journal of BUON. 18: 335-41.

Welch, H. G., Prorok, P. C., O’malley, A. J. y Kramer, B. S. 2016. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. The New England Journal of Medicine. 375: 1438-1447.

Ye J., Jia J., Dong S., Zhang C., Yu S., Li L., Mao C., Wang D., Chen J. y Yuan G. 2014. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. European Journal of Cancer Prevention. 23:158-165.

Zhu, W. y Nelson, C. M. 2013. Adipose and mammary epithelial tissue engineering. Biomatter. 3: e24630-1- e24630-6.

DOI: http://dx.doi.org/10.18633/biotecnia.v21i1.814

Enlaces refback

  • No hay ningún enlace refback.